As filed with the Securities and Exchange Commission
on October 27, 2023
Registration No. 333-___________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
COLGATE-PALMOLIVE COMPANY
(Exact Name of Registrant as Specified in Its
Charter)
Delaware |
13-1815595 |
(State or Other Jurisdiction |
(I.R.S. Employer |
of Incorporation) |
Identification Number) |
300 Park Avenue
New York, New York 10022
(212) 310-2000
(Address, Including Zip Code, and Telephone
Number,
Including Area Code, of Registrant’s
Principal Executive Offices)
JENNIFER M. DANIELS
Chief Legal Officer and Secretary
Colgate-Palmolive Company
300 Park Avenue
New York, New York 10022
(212) 310-2000
(Name, Address, Including Zip Code, and
Telephone Number,
Including Area Code, of Agent for Service)
Copies to:
Eve N. Howard
Hogan Lovells US LLP
555 13th Street NW
Washington, DC 20004
(202) 637-5600
Approximate
Date of Commencement of Proposed Sale to the Public: From time to time after the effective date of this registration statement.
If the only securities being registered on this
Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ¨
If any of the securities
being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.
x
If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. ¨
If this Form is
a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall have become effective
upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. x
If this Form is a post-effective amendment
to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes
of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
Large accelerated filer x |
|
Accelerated filer ¨ |
Non-accelerated filer ¨ |
|
Smaller reporting company ¨ |
Emerging growth company ¨ |
|
|
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 2(a)(2)(B) of the Securities Act. ¨
PROSPECTUS
Debt Securities
| · | By
this prospectus, we may offer from time to time our debt securities. |
| · | When
we offer debt securities, we will provide you with a prospectus supplement describing the
terms of the specific issue of debt securities including the offering price of the debt securities.
This prospectus may not be used to sell debt securities unless accompanied by the applicable
prospectus supplement. |
| · | We
may sell the debt securities on a continuous or delayed basis to the public through underwriters
acting individually or through a group of underwriters which may be managed or co-managed
by one or more underwriters designated by us, through agents or dealers, directly to one
or more other purchasers or by any combination of these methods of sale. We reserve the sole
right to accept, and together with any agents, dealers and underwriters, reserve the right
to reject, in whole or in part, any proposed purchase of debt securities. For additional
information on the method of sale, refer to the section entitled “Plan of Distribution”
below. |
| · | The
name or names of any agents or underwriters involved in the sale of any debt securities,
the proceeds to us from the offering, any discounts and commissions to be allowed or paid
to the agents or underwriters, all other items constituting underwriting compensation, any
discounts and commissions to be allowed or paid to dealers and any exchanges on which the
debt securities may be listed will be set forth in the prospectus supplement covering the
sales of those debt securities. |
| · | You
should read this prospectus and the accompanying prospectus supplement relating to the specific
offering of debt securities carefully before you invest. |
Investing in debt securities involves risk.
You should consider the risk factors described in any accompanying prospectus supplement and any documents incorporated by reference
before investing in our debt securities.
Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these debt securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is October 27,
2023.
TABLE OF CONTENTS
You should rely only on the information contained
or incorporated by reference in this prospectus, any accompanying prospectus supplement and any related free writing prospectus issued
or authorized by us. Neither we nor any underwriter, dealer or agent acting on our behalf has authorized any person to provide you with
different or additional information. If anyone provides you with different or additional information, you should not rely on it. Neither
we nor any underwriter, dealer or agent acting on our behalf is making an offer to sell these debt securities in any jurisdiction where
the offer or sale is not permitted. You should assume that the information contained or incorporated by reference in this prospectus,
any accompanying prospectus supplement and any related free writing prospectus issued or authorized by us is accurate only as of the
date on the front cover of this prospectus, any accompanying prospectus supplement, any applicable free writing prospectus or the document
incorporated by reference, as applicable.
Unless the context otherwise requires, references
in this prospectus supplement to “Colgate,” “we,” “us” and “our” are to Colgate-Palmolive
Company.
ABOUT THIS PROSPECTUS
This
prospectus is part of an automatic shelf registration statement on Form S-3 that we filed with the Securities and Exchange
Commission (the “SEC”) as a “well-known seasoned issuer,” as defined in Rule 405 under the Securities Act
of 1933, as amended (the “Securities Act”). By using a “shelf” registration statement, we may sell, at any time
and from time to time, in one or more offerings, the debt securities described in this prospectus and any accompanying prospectus supplement.
The term “prospectus supplement” as used in this prospectus includes any pricing supplements
relating to particular offerings of debt securities. The relevant prospectus supplements will provide the financial and other specific
terms of any particular offering of debt securities, many of which are determined at the time of pricing. Because the information provided
in the prospectus supplements may also add, delete or change information contained in this prospectus, you should rely on the information
in the applicable prospectus supplement or supplements to the extent that it is inconsistent with the information in this prospectus.
You should read this prospectus and the applicable prospectus supplement together with the additional information described under the
headings “Where You Can Find More Information” and “Incorporation of Information We File with the SEC.”
CAUTIONARY STATEMENT REGARDING FORWARD LOOKING
STATEMENTS
This prospectus and the documents incorporated
by reference in this prospectus contain statements that constitute “forward looking statements” within the meaning of Section 27A
of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, that set forth anticipated results based
on management’s current plans and assumptions.
These statements may relate, for example, to
sales or volume growth, net selling price increases, organic sales growth, profit or profit margin levels, earnings per share
levels, financial goals, the impact of foreign exchange volatility, the impact of COVID-19, the impact of the war in Ukraine, the
impact of the Israel-Hamas war, cost-reduction plans (including the 2022 Global Productivity Initiative), tax rates, interest rates,
new product introductions, digital capabilities, commercial investment levels, acquisitions, divestitures, share repurchases or
legal or tax proceedings, among other matters. In some cases, you can identify forward looking statements by terminology such as
“expect,” “anticipate,” “estimate,” “intend,” “may,” “will,”
“could,” “would,” “should,” “predict,” “potential,” “plan,”
“believe” or the negative of these terms or similar terminology.
These statements are made on the basis of our
views and assumptions as of this time and we undertake no obligation to update these statements, whether as a result of new information,
future events or otherwise, except as required by law or by the rules and regulations of the SEC. Moreover, we do not, nor does
any other person, assume responsibility for the accuracy and completeness of those statements. We caution investors that any such forward-looking
statements are not guarantees of future performance and that actual events or results may differ materially from those statements. Actual
events or results may differ materially because of factors that affect international businesses and global economic conditions, as well
as matters specific to us and the markets we serve, including the uncertain macroeconomic and political environment in different countries,
including as a result of inflation and rising interest rates, and its effect on consumer spending habits, foreign currency rate fluctuations,
exchange controls, tariffs, sanctions, price or profit controls, labor relations, changes in foreign or domestic laws or regulations
or their interpretation, political and fiscal developments, including changes in trade, tax and immigration policies, increased competition
and evolving competitive practices (including from the growth of eCommerce and the entry of new competitors and business models), the
ability to operate and respond effectively during a pandemic, epidemic or widespread public health concern, including COVID-19, the ability
to manage disruptions in our global supply chain and/or key office facilities, the ability to manage the availability and cost of raw
and packaging materials and logistics costs, the ability to maintain or increase selling prices as needed, changes in the policies of
retail trade customers, the emergence of alternative retail channels, the growth of eCommerce and the rapidly changing retail landscape
(as consumers increasingly shop online), the ability to develop innovative new products, the ability to continue lowering costs and operate
in an agile manner, the ability to maintain the security of our information technology systems from a cyber-security incident or data
breach, the ability to address the effects of climate change and achieve our sustainability and social impact goals, the ability to complete
acquisitions and divestitures as planned, the ability to successfully integrate acquired businesses, the ability to attract and retain
key employees and integrate DE&I initiatives across our organization, the uncertainty of the outcome of legal proceedings, whether
or not we believe they have merit, and the ability to address uncertain or unfavorable global economic conditions, including inflation,
disruptions in the credit markets and tax matters.
All of the forward-looking statements are qualified
in their entirety by reference to the factors discussed under the captions “Risk Factors” and “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and to the factors discussed under the caption “Risk Factors” in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023 (incorporated by reference in this prospectus)
and similar sections in our subsequent filings that we incorporate by reference in this prospectus, which describe risks and factors
that could cause results to differ materially from those projected in the forward-looking statements. Those risk factors may not be exhaustive.
We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new
risk factors, nor can we assess the impact, if any, of these new risk factors on our businesses or the extent to which any factor, or
combination of factors, may cause actual results to differ materially from those projected in any forward-looking statements. Given these
uncertainties, we caution investors not to unduly rely on forward-looking statements in making an investment decision. We are under no
obligation to (and expressly disclaim any obligation to) update or alter any forward-looking statement that may be made from time to
time, whether as a result of new information, future events or otherwise.
COLGATE-PALMOLIVE COMPANY
Colgate-Palmolive Company, which was founded
in 1806 and incorporated under the laws of the State of Delaware in 1923, is a caring, innovative growth company reimagining a healthier
future for all people, their pets and our planet. We seek to deliver sustainable, profitable growth through science-led, core and premium
innovation and superior shareholder returns, as well as provide Colgate employees with an innovative and inclusive work environment.
We do this by developing and selling products that make people’s and their pets’ lives healthier and more enjoyable and by
embracing our sustainability and social impact and diversity, equity and inclusion strategies across our organization. Our products are
marketed in over 200 countries and territories throughout the world. Our principal executive offices are located at 300 Park Avenue,
New York, New York 10022 (telephone (212) 310-2000).
We operate in two product segments: (1) Oral,
Personal and Home Care and (2) Pet Nutrition. We are a leader in Oral Care with global leadership in the toothpaste and manual toothbrush
categories according to market share data. We sell our toothpastes under brands such as Colgate, Darlie, elmex, hello, meridol, Sorriso
and Tom’s of Maine, our toothbrushes under brands such as Colgate, Darlie, elmex and meridol and our mouthwashes under brands such
as Colgate, elmex and meridol. Our Oral Care business also includes pharmaceutical products for dentists and other oral health professionals.
We are a leader in many product categories of
the Personal Care market with global leadership in liquid hand soap, according to market share data, which we sell under brands such
as Softsoap, Palmolive and Protex. Our Personal Care products also include Irish Spring, Palmolive and Protex bar soap, Palmolive, Sanex
and Softsoap shower gels, Lady Speed Stick, Sanex, Speed Stick and Tom’s of Maine deodorants and antiperspirants, EltaMD, Filorga
and PCA Skin skin health products and Palmolive shampoos and conditioners.
We manufacture and market
a wide array of products for the Home Care market, including Ajax, Axion and Palmolive dishwashing liquids and Ajax, Fabuloso and Murphy’s
Oil Soap household cleaners. We are a market leader in fabric conditioners with leading brands, including Suavitel in Latin America,
Soupline in Europe, and Cuddly in the South Pacific, according to market share data.
Through our Hill’s Pet Nutrition segment
(“Hill’s” or “Pet Nutrition”), we are a world leader in specialty pet nutrition products for dogs and cats
with products marketed in over 80 countries and territories worldwide. Hill’s markets pet foods primarily under two brands. Hill’s
Science Diet, which is called Hill’s Science Plan in Europe, is a range of products for everyday nutritional needs. Hill’s
Prescription Diet is a range of therapeutic pet foods to help nutritionally support dogs and cats in various different stages of health.
If you want to find more information about our
company, please see the filings that we incorporate by reference in this prospectus. See the sections entitled “Where You Can Find
More Information” and “Incorporation of Information We File with the SEC” in this prospectus.
RISK FACTORS
Investing in the debt securities to be offered
pursuant to this prospectus involves certain risks. For a discussion of the factors you should carefully consider before deciding to
purchase any debt securities that may be offered, please read “Risk Factors” in our most recently filed Annual Report on
Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, as well as those risk factors that may be included in the
applicable prospectus supplement and other information included or incorporated by reference in this prospectus.
USE OF PROCEEDS
We intend to use the net proceeds from the sale
of the debt securities for general corporate purposes, unless otherwise specified in the applicable prospectus supplement.
DESCRIPTION OF DEBT SECURITIES
General
We will offer the debt securities described in
this prospectus from time to time in one or more distinct series for an aggregate initial public offering price in U.S. dollars or in
foreign currencies or units of two or more currencies, based on the applicable exchange rate at the time of offering, as we shall designate
at the time of offering.
Unless otherwise specified in the applicable
prospectus supplement, the debt securities will be issued under an indenture, dated as of November 15, 1992, between our company
and The Bank of New York Mellon (formerly known as The Bank of New York), as trustee. We refer to this indenture, as supplemented from
time to time, as the “indenture” and to the trustee under the indenture as the “trustee.” The indenture has been
qualified under the Trust Indenture Act of 1939. A copy of the indenture is incorporated by reference as an exhibit to the registration
statement of which this prospectus is a part. The following summaries of material provisions of the debt securities and of the indenture
are not complete and are subject to, and qualified in their entirety by reference to, the provisions of the indenture, including the
definitions of terms.
The indenture does not limit the amount of debt,
secured or unsecured, which we may issue. The debt securities offered by this prospectus are unsecured and rank equally with our other
unsecured and unsubordinated indebtedness.
Terms of the Debt Securities
We may issue the debt securities from time to
time, without limitation as to aggregate principal amount and in one or more series. We may issue debt securities upon the satisfaction
of conditions, including the delivery to the trustee of a supplemental indenture, or a resolution of our Board of Directors or a committee
of our Board of Directors, or a certificate of our officers who have been authorized by our Board of Directors to take that kind of action,
which fixes or establishes the terms of the debt securities being issued. Any supplemental indenture, resolution or officer’s certificate
approving the issuance of any issue of debt securities will include the following terms of that issue of debt securities:
| · | the
aggregate principal amount; |
| · | the
stated maturity date; |
| · | the
date or dates on which we will pay principal, if other than at maturity, or the method we
will use to determine these dates; |
| · | whether
and how the principal amount will be determined, whether by reference to an index, formula
or other method; |
| · | the
rate or rates (or manner of calculating the rate or rates) at which the debt securities will
bear interest, if any, and the date or dates from which any interest will accrue; |
| · | the
interest payment dates and regular record dates for any interest payable; |
| · | if
in addition to or other than the Borough of Manhattan, The City of New York, the place or
places where the principal (and premium, if any) and interest, if any, will be payable, and
where the debt securities may be delivered for registration, transfer or exchange; |
| · | any
provisions for redemption of the debt securities, the redemption price or prices and any
remarketing arrangements; |
| · | any
mandatory redemption or sinking fund or analogous provisions; |
| · | whether
the debt securities are denominated or payable in United States dollars or in one or more
currencies or units of two or more currencies; |
| · | the
form in which we will issue the debt securities, whether registered, bearer or both, and
any restrictions applicable to the exchange of one form for another and/or to the offer,
sale and delivery of the debt securities in either form; |
| · | whether
and under what circumstances we will pay additional amounts under any debt securities held
by a person who is not a U.S. person for specified taxes, assessments or other governmental
charges and whether we have the option to redeem the affected debt securities rather than
pay any such additional amounts; |
| · | whether
the debt securities are to be issued in global form and if so, the depositary for the global
securities; |
| · | the
title of the debt securities and the series of which the debt securities are a part; |
| · | the
minimum denominations in which any debt securities will be issuable if other than denominations
of $1,000 and any integral multiple thereof; |
| · | any
additional covenants or events of default applicable to our company; and |
| · | any
other terms of the debt securities which are not inconsistent with the provisions of the
indenture. |
Please see the applicable prospectus supplement for the
terms of the specific debt securities being offered.
Prospective purchasers of debt securities should
be aware that special U.S. Federal income tax, accounting and other considerations may be applicable to instruments such as the debt
securities. The prospectus supplement relating to an issue of debt securities will describe these considerations, if they apply.
The provisions of the indenture permit us, without
the consent of the holders of any debt securities, to issue additional debt securities with terms different from those of debt securities
previously issued and to reopen a previous series of debt securities and issue additional debt securities of that series.
The indenture does not contain any provisions
which would provide protection to holders of debt securities against a sudden and dramatic decline in credit quality resulting from a
takeover, a recapitalization or other highly leveraged transaction involving Colgate.
We will pay or deliver principal and any premium,
additional amounts and interest in the manner, at the places and subject to the restrictions set forth in the indenture, the debt securities
and the applicable prospectus supplement. However, at our option, we may pay any interest by check mailed to the holders of registered
debt securities at their registered addresses.
Holders may present debt securities for exchange,
and registered debt securities for transfer or exchange, in the manner, at the places and subject to the restrictions set forth in the
indenture, the debt securities and the prospectus supplement. Holders may transfer debt securities in bearer form for registered debt
securities by delivering the bearer debt securities and related coupons, if any, to the office or agency of the registrar for that series
of debt securities. If any series of debt securities is issued in global form, the prospectus supplement will describe the circumstances,
if any, under which beneficial owners of interests in any global debt security may exchange those interests for definitive debt securities
of that same series and of like tenor and principal amount, in any authorized form and denomination. There will be no service charge
for any transfer or exchange of debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental
charge payable in connection with a transfer or exchange other than certain exchanges not involving any transfer.
Merger and Consolidation
We may consolidate or merge with or into any
other corporation, and we may sell, lease or convey all or substantially all of our assets to any corporation, provided that:
| · | the
resulting corporation, if other than Colgate, is a corporation organized and existing under
the laws of the United States of America or any U.S. state or the District of Columbia and
assumes all of our obligations to: |
| 1. | pay or deliver the principal of or any premium, interest or additional
amounts on the debt securities; and |
| 2. | perform and observe all of our other obligations under the indenture,
and |
| · | we
or any successor corporation, as the case may be, are not, immediately after any such consolidation,
merger or sale of assets, in default under the indenture. |
Modification and Waiver
We and the trustee may, without the consent of
holders, modify provisions of the indenture for specified purposes, including, among other things, curing ambiguities and correcting
inconsistencies. We and the trustee may modify and amend other provisions of the indenture with the consent of holders of at least a
majority in principal amount of each series of debt securities affected. However, the consent of each holder of any debt security affected
must be obtained if the amendment or modification:
| · | changes
the stated maturity of the principal of, or any premium or installment of interest or additional
amounts on, any debt security; |
| · | reduces
the principal amount due and payable at maturity or upon acceleration of maturity of, or
the rate of interest or additional amounts payable on, or any premium payable on redemption
or otherwise on, any debt security; |
| · | adversely
affects any right of repayment at the option of the holders; |
| · | changes
the place of delivery of, or currency of, the payment of principal or any premium, interest
or additional amounts on any debt security or impairs the right to institute suit for the
enforcement of any such payment or delivery; |
| · | reduces
the percentage in principal amount or aggregate issue price of the outstanding debt securities
of any series, the consent of whose holders is required to modify or amend the indenture;
or |
| · | modifies
the foregoing requirements or reduces the percentage to less than a majority in principal
amount of outstanding debt securities necessary to waive certain past defaults by Colgate
under the indenture. |
The holders of at least a majority in principal
amount of the outstanding debt securities of any series may, with respect to that series, waive past defaults under the indenture and
waive our compliance with certain provisions of the indenture, except as described under “—Events of Default.”
Events of Default
Except as otherwise provided in the applicable
prospectus supplement, each of the following constitutes an event of default with respect to each series of debt securities issued under
the indenture:
| · | default
in the payment of any interest or additional amounts when due and continuing for 30 days; |
| · | default
in the payment of any principal or premium when due and payable at maturity; |
| · | default
in the payment of any sinking fund payment when due; |
| · | default
in the performance, or breach, of any other obligation of ours under the indenture, or under
provisions of a series of debt securities that are applicable to all series of debt securities,
and continuance of the default for 60 days after we are given written notice of the default
as provided in the indenture; |
| · | specified
events of bankruptcy, insolvency or reorganization of Colgate; and |
| · | any
other event of default with respect to debt securities of that series. |
If an event of default occurs and is continuing
for any series of debt securities, the trustee or the holders of at least 25% in principal amount of the outstanding debt securities
of that series may declare the principal of all the debt securities of that series, or any lesser amount provided for in the debt securities
of that series, due and payable immediately. At any time after such a declaration of acceleration with respect to the debt securities
of any series has been made, but before the trustee has obtained a judgment or decree for payment of the money due, the holders of a
majority in principal amount of the outstanding debt securities of that series by written notice may rescind any declaration of acceleration
and its consequences, provided that all payments and/or deliveries due, other than those due as a result of acceleration, have been made
and all other events of default have been remedied or waived.
The holders of at least a majority in principal
amount of the outstanding debt securities of any series may waive an event of default with respect to that series, except a default:
| · | in
the payment of any amounts due and payable or deliverable under the debt securities of that
series; or |
| · | in
respect of an obligation of ours contained in, or a provision of, the indenture which cannot
be modified under the terms of the indenture without the consent of each holder of outstanding
debt securities affected. |
The holders of a majority in principal amount
of the outstanding debt securities of a series may direct the time, method and place of conducting any proceeding for any remedy available
to the trustee or exercising any trust or power conferred on the trustee with respect to debt securities of that series, provided that
the direction is not in conflict with any rule of law, the indenture or the debt securities of that series. The trustee must, within
90 days after a default occurs notify the holders of the applicable series of debt securities of the default, unless the default is cured
or waived. The trustee may withhold notice of default, except default in payment of principal, any premium, interest or sinking fund
payment, if it determines that it is in the interest of the holders to do so. Before proceeding to exercise any right or power under
the indenture at the direction of the holders, the trustee is entitled to receive from those holders reasonable security or indemnity
against the costs, expenses and liabilities which might be incurred by it in complying with any such direction.
Unless otherwise stated in the prospectus supplement,
any series of debt securities issued under the indenture will not have the benefit of any cross-default provisions with other indebtedness
of our company.
We will be required to furnish to the trustee
annually a statement as to our performance of all of our obligations and conditions under the indenture.
Limitations Upon Liens
The debt securities will not be secured by any
mortgage, pledge or other lien. Unless a prospectus supplement with respect to a particular series of debt securities states otherwise,
the covenants described below will apply to each series of debt securities.
We covenant in the indenture not to create or
suffer to exist, or permit any of our Principal Domestic Subsidiaries (as defined below) to create or suffer to exist, any Lien (as defined
below) on any Restricted Property (as defined below), whether owned on the date of the indenture or thereafter acquired, without making
effective provision (and we covenant and agree in the indenture that we will make or cause to be made effective provision) whereby the
debt securities shall be directly secured by such Lien equally and ratably with (or prior to) all other indebtedness secured by such
Lien as long as such other indebtedness shall be so secured; provided, however, that there shall be excluded from the foregoing restrictions:
| · | Liens
securing Debt (as defined below) not exceeding $10,000,000 which are existing on the date
of the indenture on Restricted Property; and, if any property owned or leased as of the date
of the indenture by us or one of our Principal Domestic Subsidiaries at any time thereafter
becomes a Principal Domestic Manufacturing Property, any Liens existing on the date of the
indenture on such property securing the Debt secured or evidenced thereby on the date of
the indenture; |
| · | Liens
on Restricted Property of a Principal Domestic Subsidiary (as defined below) as a security
for Debt of such Subsidiary to us or to another Principal Domestic Subsidiary; |
| · | in
the case of any corporation which becomes a Principal Domestic Subsidiary after the date
of the indenture, Liens on Restricted Property of such Principal Domestic Subsidiary which
are in existence at the time it becomes a Principal Domestic Subsidiary and which were not
incurred in contemplation of it becoming a Principal Domestic Subsidiary; |
| · | any
Lien existing prior to the time of acquisition of any Principal Domestic Manufacturing Property
acquired by us or one of our Principal Domestic Subsidiaries after the date of the indenture
through purchase, merger, consolidation or otherwise; |
| · | any
Lien on any Principal Domestic Manufacturing Property (other than a Major Domestic Manufacturing
Property (as defined below)) acquired or constructed by our company or a Principal Domestic
Subsidiary after the date of the indenture which is placed on such Property at the time of
or within 180 days after the acquisition thereof or prior to, at the time of or within 180
days after completion of construction thereof to secure all or a portion of the price of
such acquisition or construction or funds borrowed to pay all or a portion of the price of
such acquisition or construction; |
| · | extensions,
renewals or replacements of any Lien referred to in the first, third, fourth or fifth bullet
points above to the extent that the principal amount of the Debt secured or evidenced thereby
is not increased, provided that the Lien is not extended to any other Restricted Property; |
| · | Liens
imposed by law, such as carriers’, warehousemen’s, mechanics’, materialmen’s,
vendors’ and landlords’ liens, and liens arising out of judgments or awards against
us or any of our Principal Domestic Subsidiaries with respect to which we or such Subsidiary
at the time shall currently be prosecuting an appeal or proceedings for review and with respect
to which it shall have secured a stay of execution pending such appeal or proceedings for
review; |
| · | Liens
securing the payment of taxes, assessments and governmental charges or levies, either (1) not
delinquent or (2) being contested in good faith by appropriate legal or administrative
proceedings and as to which we or a Principal Domestic Subsidiary, as the case may be, to
the extent required by generally accepted accounting principles applied on a consistent basis,
shall have set aside on its books adequate reserves; |
| · | minor
survey exceptions, minor encumbrances, easements or reservations of, or rights of others
for, rights of way, sewers, electric lines, telegraph and telephone lines and other similar
purposes and zoning or other restrictions as to the use of any Principal Domestic Manufacturing
Property, which exceptions, encumbrances, easements, reservations, rights and restrictions
do not, in our opinion, in the aggregate materially detract from the value of such Principal
Domestic Manufacturing Property or materially impair its use in the operation of our business
and that of our Principal Domestic Subsidiaries; and |
| · | any
Lien on Restricted Property not referred to above if, at the time such Lien is created, incurred,
assumed or suffered to be created, incurred or assumed, and after giving effect thereto and
to the Debt secured or evidenced thereby, the aggregate amount of all our outstanding Debt
together with that of our Principal Domestic Subsidiaries secured or evidenced by Liens on
Restricted Property which are not referred to above and which do not equally and ratably
secure the debt securities, shall not exceed 15% of Consolidated Net Tangible Assets. |
“Consolidated Net Tangible Assets”
means the aggregate amount of assets (less applicable reserves and other properly deductible items) after deducting therefrom (1) all
current liabilities and (2) all goodwill, trade names, trademarks, patents, unamortized debt discount and expense and other like
intangibles of ours and our consolidated subsidiaries, all as set forth on the most recent balance sheet of ours and our consolidated
subsidiaries prepared in accordance with generally accepted accounting principles as practiced in the United States.
“Debt” means (1) indebtedness
for borrowed money, (2) obligations evidenced by bonds, debentures, notes or other similar instruments, (3) obligations to
pay the deferred purchase price of property or services (other than accounts payable in the ordinary course of business), (4) obligations
as a lessee under leases which shall have been or should be, in accordance with generally accepted accounting principles, recorded as
capital leases, and (5) obligations under direct or indirect guaranties in respect of, and obligations (contingent or otherwise)
to purchase or otherwise acquire, or otherwise to assure a creditor against loss in respect of, indebtedness or obligations of others
of the kinds referred to in clauses (1) through (4) above.
“Domestic Subsidiary” means any Subsidiary
a majority of the business of which is conducted within the United States of America, or a majority of the properties and assets of which
are located within the United States of America, except any Subsidiary whose assets consist substantially of the securities of Subsidiaries
which are not Domestic Subsidiaries.
“Instruments” of any corporation
means and includes (1) all capital stock of all classes of and all other equity interests in such corporation and all rights, options
or warrants to acquire the same, and (2) all promissory notes, debentures, bonds and other evidences of Debt of such corporation.
“Lien” means
any mortgage, lien, pledge, security interest, encumbrance or charge of any kind, any conditional sale or other title retention agreement
or any lease in the nature thereof, provided that the term “Lien” shall not include any lease involved in a sale and lease-back
transaction.
“Major Domestic Manufacturing Property”
means any Principal Domestic Manufacturing Property the net depreciated book value of which on the date as of which the determination
is made exceeds 3% of the Consolidated Net Tangible Assets.
“Principal Domestic Manufacturing Property”
means any building, structure or facility (including the land on which it is located and the improvements and fixtures constituting a
part thereof) used primarily for manufacturing or processing which is owned or leased by us or any of our Subsidiaries, is located in
the United States of America and the net depreciated book value of which on the date as of which the determination is made exceeds 1%
of Consolidated Net Tangible Assets, except any such building, structure or facility which our Board of Directors by resolution declares
is not of material importance to the total business conducted by us and our Subsidiaries as an entirety.
“Principal Domestic Subsidiary” means
(1) each Subsidiary which owns or leases a Principal Domestic Manufacturing Property, (2) each Domestic Subsidiary the consolidated
net worth of which exceeds 3% of Consolidated Net Tangible Assets (as set forth in the most recent financial statements delivered pursuant
to the indenture) and (3) each Domestic Subsidiary of each Subsidiary referred to in the foregoing clause (1) or (2) except
any such Subsidiary the accounts receivable and inventories of which have an aggregate net book value of less than $5,000,000.
“Restricted Property” means and includes
(1) all Principal Domestic Manufacturing Properties, (2) all Instruments of all Principal Domestic Subsidiaries and (3) all
inventories and accounts receivable of ours and our Principal Domestic Subsidiaries.
“Subsidiary” means any Corporation
of which at the time of determination we or one or more of our Subsidiaries owns or controls directly or indirectly more than 50% of
the shares of Voting Stock.
“Voting Stock” means stock of a Corporation
of the class or classes having general voting power under ordinary circumstances to elect at least a majority of the board of directors,
managers or trustees of such Corporation, provided that, for this purpose, stock which carries only the right to vote conditionally on
the happening of an event shall not be considered voting stock whether or not such event shall have happened.
Other capitalized terms used but not defined in this prospectus
shall have the meaning given those terms in the indenture.
Legal Defeasance and Covenant Defeasance
We at any time may terminate as to a series of
debt securities all of our obligations (except for certain obligations regarding the defeasance trust and obligations to register the
transfer or exchange of a debt security, to replace destroyed, lost or stolen debt securities and any related coupons and to maintain
agencies with respect to the debt securities) arising under the indenture and the debt securities and coupons of that series. This option
of ours is called a “legal defeasance.” We at any time may terminate as to a series of debt securities, among other obligations,
our obligations arising under the covenant described under “Limitations Upon Liens” above. This option of ours is called
a “covenant defeasance.”
We may exercise our legal defeasance option with
respect to a series of debt securities even if we have previously exercised our covenant defeasance option in regard to that series of
debt securities. If we exercise our legal defeasance option with respect to a series of debt securities, that series may not be accelerated
because of an Event of Default. If we exercise our covenant defeasance option with respect to a series of debt securities, that series
may not be accelerated on the basis of breaches of the defeased covenant.
To exercise either option as to a series of debt
securities, we must deposit in trust with the trustee cash or United States government obligations sufficient to pay the principal of,
premium, if any, and interest on the debt securities of that series at their maturity or redemption and must comply with other specified
conditions. In particular, we must obtain an opinion of tax counsel that the defeasance will not result in recognition for United States
Federal income tax purposes of any gain or loss to holders of the series of debt securities. The opinion of tax counsel, in the case
of legal defeasance, must refer to and be based upon a ruling of the Internal Revenue Service or a change in applicable United States
Federal income tax law occurring after the date of the indenture.
Concerning the Trustee
The Bank of New York Mellon serves as trustee
under the indenture and is the security registrar and paying agent with respect to the debt securities. The indenture provides that,
except during the continuance of an Event of Default, the trustee will perform only such duties as are specifically set forth in the
indenture. During the existence of an Event of Default, the trustee will exercise such rights and powers vested in it under the indenture
and use the same degree of care and skill in its exercise as a prudent person would exercise under the circumstances in the conduct of
such person’s own affairs.
The indenture contains certain limitations on
the right of the trustee, should it become a creditor of ours, to obtain payment of claims in certain cases, or to realize on certain
property received in respect of any such claim as security or otherwise. The trustee is permitted to engage in other transactions with
us; provided, however, that if the trustee acquires any conflicting interest it must eliminate such conflict or resign.
The trustee’s principal corporate trust
office is located at 240 Greenwich Street, New York, New York 10286. We have banking relationships with The Bank of New York Mellon and
certain of its affiliates.
Governing Law
The indenture and the debt securities will be
governed by, and construed in accordance with, the laws of the State of New York.
PLAN OF DISTRIBUTION
We may sell debt securities:
| · | to
the public through underwriters acting individually or through a group of underwriters which
may be managed or co-managed by one or more underwriters designated by us, |
| · | through
agents or dealers, |
| · | directly
to one or more other purchasers, or |
| · | by
any combination of these methods of sale. |
The prospectus supplement with respect to the
particular series of debt securities being offered will describe the terms of the offering of that series, including the name or names
of any agents or underwriters, the public offering or purchase price, the proceeds to us from the offering, any discounts and commissions
to be allowed or paid to the agents or underwriters, all other items constituting underwriting compensation, any discounts and commissions
to be allowed or paid to dealers, any initial public offering price and any exchanges on which the debt securities may be listed. Underwriters,
dealers and agents that participate in the distribution of the debt securities may be deemed to be underwriters, and any discounts or
commissions received by them from us and any profit on the resale of the debt securities by them may be deemed to be underwriting discounts
and commissions, under the Securities Act.
Under certain circumstances, we may repurchase
debt securities and reoffer them to the public as set forth above. We may also arrange for repurchases and resales of the debt securities
by dealers.
No particular offering of debt securities will
have an established trading market when issued. Unless specified in the applicable prospectus supplement, we will not list the debt securities
on any securities exchange. The underwriters may from time to time purchase and sell debt securities in the secondary market, but they
are not obligated to do so, and there can be no assurance that there will be a secondary market for the notes or liquidity in the secondary
market if one develops. In addition, the underwriters may discontinue any market-making activity at any time.
To facilitate a debt securities offering, any
underwriter may engage in over-allotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation
M under the Securities Exchange Act of 1934, as amended.
| · | Over-allotment
involves sales in excess of the offering size, which creates a short position. |
| · | Stabilizing
transactions permit bids to purchase the underlying security so long as the stabilizing bids
do not exceed a specified maximum. |
| · | Short
covering transactions involve purchases of the securities in the open market after the distribution
is completed to cover short positions. |
| · | Penalty
bids permit the underwriters to reclaim a selling concession from a dealer when the securities
originally sold by the dealer are purchased in a covering transaction to cover short positions. |
Those activities may cause the price of the securities
to be higher than it would otherwise be. If commenced, the underwriters may discontinue those activities at any time.
If so indicated in the prospectus supplement,
we will authorize underwriters to solicit offers by certain institutions to purchase debt securities from us pursuant to delayed delivery
contracts providing for payment and delivery on the date stated in the prospectus supplement. Each contract will be for an amount not
less than, and, unless we otherwise agree, the aggregate principal amount of debt securities sold pursuant to the contracts shall not
be more than, the respective amounts stated in the prospectus supplement. Institutions with whom the contracts, when authorized, may
be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions,
and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts will not be subject to any conditions
except that the purchase by an institution of the debt securities covered under any such contract shall not at the time of delivery be
prohibited under the laws of any jurisdiction in the United States to which that institution is subject.
We have agreed to indemnify the agents and the
underwriters against certain civil liabilities, including liabilities under the Securities Act, or to contribute to payments the agents
or the underwriters may be required to make in connection with those liabilities. Agents, underwriters and dealers may be customers of
ours, engage in transactions with us, or perform services for us in the ordinary course of business.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available over the Internet on the SEC’s website at http://www.sec.gov
and on our website at http://www.colgatepalmolive.com. Our common stock is listed and traded on the New York Stock Exchange under the
trading symbol, “CL.” Information about us is also available at our website at www.colgatepalmolive.com. However, the information
on our website is not a part of this prospectus.
We have filed this registration statement on
Form S-3 with the SEC covering the debt securities. For further information on us and the debt securities, you should refer to our
registration statement and its exhibits. This prospectus summarizes certain provisions of contracts and other documents that we refer
you to. Because the prospectus may not contain all the information that you may find important, you should review the full text of these
documents. We have included copies of these documents as exhibits to our registration statement of which this prospectus is a part.
INCORPORATION OF INFORMATION WE FILE WITH THE SEC
The SEC allows us to incorporate by reference the information
we file with them, which means:
| · | incorporated
documents are considered part of this prospectus; |
| · | we
can disclose important information to you by referring you to those documents; and |
| · | information
that we file with the SEC will automatically update and, to the extent inconsistent, supersede
this prospectus and previously incorporated information. |
We incorporate by reference the documents listed
below which we filed with the SEC under the Securities Exchange Act of 1934, as amended (except that we do not incorporate by reference
any portion of a document that is deemed, under SEC rules, to have been furnished and not filed):
|
· |
Current Reports on Form 8-K filed January 12, 2023, January 30, 2023, March 1, 2023, May 17, 2023, August 18, 2023 and September 15, 2023. |
We also incorporate by reference each of the
following documents that we will file with the SEC after the date of this prospectus until this offering is completed:
| · | all
documents filed under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including
definitive proxy or information statements filed under Section 14 of the Exchange Act
in connection with any subsequent stockholders’ meeting (other than information in
the documents that is deemed to have been furnished and not filed). |
You should rely only on information contained
or incorporated by reference in this prospectus, any accompanying prospectus supplement and any related free writing prospectus issued
or authorized by us. Neither we nor any agent or underwriter acting on our behalf has authorized any person to provide you with different
or additional information. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor
any agent or underwriter acting on our behalf is making an offer to sell these securities in any jurisdiction where the offer or sale
is not permitted.
You should assume that the information appearing
in this prospectus is accurate as of the date of this prospectus only. Our business, financial condition and results of operations may
have changed since that date.
You may request a copy of
any filings referred to above (excluding exhibits that are not specifically incorporated by reference therein), at no cost, by contacting
us at the following address: Investor Relations, Colgate-Palmolive Company, 300 Park Avenue, New York, New York 10022-7499, Telephone:
(212) 310-2000, E-mail: Investor_Relations@colpal.com.
VALIDITY OF THE DEBT SECURITIES
The validity of the debt securities will be passed
upon for us by Hogan Lovells US LLP, Washington, District of Columbia.
EXPERTS
The financial statements and management’s
assessment of the effectiveness of internal control over financial reporting (which is included in Management’s Report on Internal
Control over Financial Reporting) incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2022 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public
accounting firm, given on the authority of said firm as experts in auditing and accounting.
PART II.
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution
The following table sets forth the expenses in
connection with the issuance and distribution of the securities being registered, other than underwriting discounts and commissions.
All of the amounts shown are estimates.
Securities and Exchange Commission Registration Fee | |
$ | |
(1) |
Legal Fees and Expenses | |
| |
(2) |
Services of Independent Registered Public Accounting Firm | |
| |
(2) |
Printing Expenses, including Engraving | |
| |
(2) |
Trustee’s Fees and Expenses | |
| |
(2) |
Miscellaneous Expenses | |
| |
(2) |
Total | |
$ | |
(2) |
| (1) | The
Registrant is registering an indeterminate amount of securities under this Registration Statement
and in accordance with Rules 456(b) and 457(r), the Registrant is deferring payment
of all of the registration fee. |
| (2) | The
applicable prospectus supplement will set forth the estimated aggregate amount of expenses
payable in respect of any offering of securities. |
Item 15. Indemnification of Directors and Officers
Reference is made to Section 145 of the
General Corporation Law of the State of Delaware (the “GCL”), which provides for indemnification of directors, officers and
other employees in certain circumstances, and to Section 102(b)(7) of the GCL, which provides for the elimination or limitation
of the personal liability for monetary damages of directors under certain circumstances. Article Tenth of the Restated Certificate
of Incorporation of the Company, as amended, eliminates the personal liability for monetary damages of directors under certain circumstances
and provides indemnification to directors, officers and other employees of the Company to the fullest extent permitted by the GCL. The
Company has also executed indemnification agreements with the directors, officers and certain other employees of the Company. Such indemnification
agreements contain provisions which purport to provide indemnification, where not limited by applicable law, for amounts paid by such
individuals in settlement of shareholder derivative actions. Additionally, the Company maintains customary directors’ and officers’
liability insurance.
Item 16. Exhibits
| 1.1 | Form of Underwriting Agreement
for debt securities* |
| 4.1 | Indenture,
dated as of November 15, 1992, between the Company and The Bank of New York Mellon (formerly
known as The Bank of New York), as Trustee (incorporated by reference from Exhibit 4.1
to the Company’s Form S-3 Registration Statement and Post-Effective Amendment
No. 1 filed on June 26, 1992, Registration No. 33-48840)** |
| 4.2 | Form of
debt security* |
| 5.1 | Opinion of Hogan Lovells US LLP |
| 23.1 | Consent of Hogan Lovells US LLP
(included in Exhibit 5.1) |
| 23.2 | Consent of PricewaterhouseCoopers
LLP |
| 24.1 | Powers of Attorney |
| 25.1 | Statement
of Eligibility on Form T-1 of The Bank of New York Mellon, as Trustee under the Trust
Indenture Act of 1939, as amended and with respect to the Indenture, dated as of November 15,
1992 |
| 107 | Filing Fee Table |
* To be filed by amendment or as an exhibit to a Current Report on
Form 8-K and incorporated herein by reference, if applicable.
** Paper filing.
Item 17. Undertakings
| (a) | The undersigned registrant hereby undertakes: |
| (1) | To file, during any period in which offers or sales are being made,
a post-effective amendment to this registration statement: |
| (i) | To include any prospectus required by Section 10(a)(3) of
the Securities Act of 1933; |
| (ii) | To reflect in the prospectus any facts or events arising after the
effective date of the registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change in the information
set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease
in volume of securities offered (if the total dollar value of the securities offered would
not exceed that which was registered) and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of prospectus filed with the Commission
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
no more than a 20 percent change in the maximum aggregate offering price set forth in the
“Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement; |
| (iii) | To include any material information with respect to the plan of
distribution not previously disclosed in the registration statement or any material change
to such information in the registration statement; |
provided,
however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the information required to be included
in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant
pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration
statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
| (2) | That, for the purpose of determining any liability under the Securities
Act of 1933, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof. |
| (3) | To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of the offering. |
| (4) | That, for the purpose of determining liability under the Securities
Act of 1933 to any purchaser: |
| (i) | Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall
be deemed to be part of the registration statement as of the date the filed prospectus was
deemed part of and included in the registration statement; and |
| (ii) | Each prospectus required to be filed pursuant to Rule 424(b)(2),
(b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B
relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for
the purpose of providing the information required by section 10(a) of the Securities
Act of 1933 shall be deemed to be part of and included in the registration statement as of
the earlier of the date such form of prospectus is first used after effectiveness or the
date of the first contract of sale of securities in the offering described in the prospectus.
As provided in Rule 430B, for liability purposes of the issuer and any person that is
at that date an underwriter, such date shall be deemed to be a new effective date of the
registration statement relating to the securities in the registration statement to which
the prospectus relates, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof. Provided, however, that no statement
made in a registration statement or prospectus that is part of the registration statement
or made in a document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will, as to a purchaser
with a time of contract of sale prior to such effective date, supersede or modify any statement
that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such effective date. |
| (5) | That, for the purpose of determining liability of the registrant
under the Securities Act of 1933 to any purchaser in the initial distribution of the securities,
the undersigned registrant undertakes that in a primary offering of securities of the undersigned
registrant pursuant to this registration statement, regardless of the underwriting method
used to sell the securities to the purchaser, if the securities are offered or sold to such
purchaser by means of any of the following communications, the undersigned registrant will
be a seller to the purchaser and will be considered to offer or sell such securities to such
purchaser: |
| (i) | Any preliminary prospectus or prospectus of the undersigned registrant
relating to the offering required to be filed pursuant to Rule 424; |
| (ii) | Any free writing prospectus relating to the offering prepared by
or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; |
| (iii) | The portion of any other free writing prospectus relating to the
offering containing material information about the undersigned registrant or its securities
provided by or on behalf of the undersigned registrant; and |
| (iv) | Any other communication that is an offer in the offering made by
the undersigned registrant to the purchaser. |
| (b) | The undersigned registrant hereby undertakes that, for purposes of determining
any liability under the Securities Act of 1933, each filing of the registrant’s annual
report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange
Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual
report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is
incorporated by reference in the registration statement shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof. |
Insofar as indemnification for liabilities arising
under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the provisions
referred to in Item 15 of this registration statement, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed
by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3
and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in The City
of New York, State of New York, on October 27, 2023.
|
|
Colgate-Palmolive
Company |
|
|
(Registrant) |
|
|
|
By: |
/s/ Noel
R. Wallace |
|
|
Noel R. Wallace |
|
|
Chairman of the Board, |
|
|
President and Chief Executive Officer |
Pursuant to the requirements of the Securities
Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
Principal Executive Officer and Director: |
|
|
|
|
|
|
|
|
|
|
|
Chairman of the
Board, President and Chief |
|
October 27,
2023 |
/s/ Noel R. Wallace |
|
Executive Officer |
|
|
Noel
R. Wallace |
|
|
|
|
|
|
|
|
|
Principal Financial Officer: |
|
|
|
|
|
|
Chief Financial Officer |
|
October 27, 2023 |
/s/ Stanley J. Sutula III |
|
|
|
|
Stanley
J. Sutula III |
|
|
|
|
|
|
|
|
|
Principal Accounting Officer: |
|
|
|
|
|
|
Executive Vice President and
Controller |
|
October 27, 2023 |
/s/ Gregory O. Malcolm |
|
|
|
|
Gregory
O. Malcolm |
|
|
|
|
|
|
|
|
|
All Other Directors: |
|
|
|
|
|
|
|
|
|
* |
|
Director |
|
October 27, 2023 |
|
|
|
|
|
John
P. Bilbrey |
|
|
|
|
|
|
|
|
|
* |
|
Director |
|
October 27, 2023 |
|
|
|
|
|
John
T. Cahill |
|
|
|
|
|
|
|
|
|
* |
|
Director |
|
October 27, 2023 |
|
|
|
|
|
Steven
A. Cahillane |
|
|
|
|
|
|
|
|
|
* |
|
Director |
|
October 27, 2023 |
|
|
|
|
|
Lisa
M. Edwards |
|
|
|
|
|
|
|
|
|
* |
|
Director |
|
October 27, 2023 |
|
|
|
|
|
C. Martin
Harris |
|
|
|
|
* |
|
Director |
|
October 27,
2023 |
|
|
|
|
|
Martina
Hund-Mejean |
|
|
|
|
|
|
|
|
|
* |
|
Director |
|
October 27,
2023 |
|
|
|
|
|
Kimberly
A. Nelson |
|
|
|
|
|
|
|
|
|
* |
|
Director |
|
October 27,
2023 |
|
|
|
|
|
Lorrie M. Norrington |
|
|
|
|
|
|
|
|
|
* |
|
Director |
|
October 27,
2023 |
|
|
|
|
|
Steven I. Sadove |
|
|
|
|
*By: |
/s/ Stanley
J. Sutula III |
|
|
Stanley J. Sutula III, Attorney-in-Fact |
|
Exhibit 5.1
|
Hogan Lovells US LLP
Columbia Square
555 Thirteenth Street, NW
Washington, DC 20004
T +1 202 637 5600
F +1 202 637 5910
www.hoganlovells.com |
October 27, 2023
Board of Directors
Colgate-Palmolive Company
300 Park Avenue
New York, New York, 10022
To the addressee referred to above:
We are acting as counsel to Colgate-Palmolive
Company, a Delaware corporation (the “Company”), in connection with its registration statement on Form S-3, as
amended (the “Registration Statement”), filed with the Securities and Exchange Commission (the “Commission”)
under the Securities Act of 1933, as amended (the “Act”), relating to the offering from time to time of the Company’s
debt securities (the “Securities”). This opinion letter is furnished to you at your request to enable you to fulfill
the requirements of Item 601(b)(5) of Regulation S-K, 17 C.F.R. § 229.601(b)(5), in connection with the Registration
Statement.
For purposes of this opinion letter, we have
examined copies of such agreements, instruments and documents as we have deemed an appropriate basis on which to render the opinions
hereinafter expressed. In our examination of the aforesaid documents, we have assumed the genuineness of all signatures, the legal
capacity of all natural persons, the accuracy and completeness of all documents submitted to us, the authenticity of all original documents,
and the conformity to authentic original documents of all documents submitted to us as copies (including pdfs). As to all matters of
fact, we have relied on the representations and statements of fact made in the documents so reviewed, and we have not independently established
the facts so relied on. This opinion letter is given, and all statements herein are made, in the context of the foregoing.
To the extent that the obligations of the Company
with respect to the Securities may be dependent upon such matters, we assume for purposes of this opinion that, as of the date hereof
and at the time of the offer, issuance and sale of any Securities, The Bank of New York Mellon (formerly known as the Bank of New York),
as successor trustee (the “Trustee”) is duly organized, validly existing and in good standing under the laws of its
jurisdiction of organization; that the Trustee is duly qualified to engage in the activities contemplated by the Indenture dated as of
November 15, 1992 between the Company and the Trustee (the “Indenture”); that the Indenture has been duly authorized,
executed and delivered by the Trustee and constitutes the legal, valid and binding obligation of the Trustee enforceable against the
Trustee in accordance with its terms; that the Trustee is in compliance with respect to performance of its obligations under the Indenture
with all applicable laws, rules and regulations; and that the Trustee has the requisite organizational and legal power and authority
to perform its obligations under the Indenture. We further assume for purposes of this opinion that at the time of the offer, issuance
and sale of any Securities, the Registration Statement is effective under the Act and no stop order suspending its effectiveness will
have been issued and remain in effect.
Hogan Lovells US
LLP is a limited liability partnership registered in the state of Delaware. “Hogan Lovells” is an international legal practice
that includes Hogan Lovells US LLP and Hogan Lovells International LLP, with offices in: Alicante Amsterdam Baltimore Beijing Birmingham
Boston Brussels Colorado Springs Denver Dubai Dusseldorf Frankfurt Hamburg Hanoi Ho Chi Minh City Hong Kong Houston Johannesburg London
Los Angeles Luxembourg Madrid Mexico City Miami Milan Minneapolis Monterrey Munich New York Northern Virginia Paris Philadelphia Rome
San Francisco São Paulo Shanghai Silicon Valley Singapore Sydney Tokyo Warsaw Washington, D.C. Associated Offices: Budapest Jakarta
Riyadh Shanghai FTZ Ulaanbaatar. Business Service Centers: Johannesburg Louisville. Legal Services Center: Berlin. For more information
see www.hoganlovells.com
Colgate-Palmolive
Company |
-
2 - |
October 27,
2023 |
For purposes of this opinion letter, we have
assumed that, at or prior to the time of the delivery of any such Security, (i) the resolutions of the Board of Directors (the “Board”)
of the Company pursuant to which the Board authorized the issuance and sale of the Securities remain in full force and effect; (ii) no
Events of Default (as defined in the Indenture) have occurred and are continuing and no rights under the Indenture have been waived by
any party thereto since the date of the Indenture; (iii) the Indenture has not been amended, restated, modified, supplemented or
terminated; (iv) a duly authorized officer of the Company shall have duly established the terms of such Security and duly authorized
the issuance and sale of such Security and such authorization shall not have been modified or rescinded; (v) the Company shall not,
by issuing any such Security, exceed the aggregate issuance authority specified by the Board in respect of securities of the same class
as the Securities; (vi) the Company shall remain validly existing as a corporation in good standing under the Delaware General Corporation
Law; and (vii) the issuance and sale of the Security will not result in a violation of any provision of any instrument or agreement
then binding upon the Company, or violate any restriction imposed by any court or governmental body having jurisdiction over the Company.
We have also assumed that, at or prior to the time of the delivery of any such Security, there shall not have occurred any change in
law affecting the validity or enforceability of such Security and none of the terms of any Security to be established subsequent to the
date hereof, nor the issuance and delivery of such Security, nor the compliance by the Company with the terms of such Security, will
violate any applicable law or public policy.
This opinion letter is based as to matters of
law solely on the Delaware General Corporation Law, as amended, and under the laws of the State of New York (but not including any laws,
statutes, ordinances, administrative decisions, rules or regulations of any political subdivision below the state level). We express
no opinion herein as to any other statutes, rules or regulations (and in particular, we express no opinion as to any effect that
such other statutes, rules or regulations may have on the opinions expressed herein).
Based upon, subject to and limited by the foregoing,
we are of the opinion that upon due execution, authentication, issuance and delivery of the Securities in accordance with the Indenture
and the applicable underwriting, agency or distribution agreement against payment therefor, the Securities will constitute valid and
binding obligations of the Company.
The opinion expressed herein with respect to
the valid and binding nature of obligations may be limited by bankruptcy, insolvency, reorganization, receivership, moratorium or other
laws affecting creditors’ rights and remedies (including, without limitation, the effect of statutory and other law regarding fraudulent
conveyances and fraudulent, and preferential or voidable transfers) and by the exercise of judicial discretion and the application of
principles of equity, good faith, fair dealing, reasonableness, conscionability and materiality (regardless of whether the Securities
are considered in a proceeding in equity or at law), including, without limitation, principles limiting the availability of specific
performance and injunctive relief.
We note that, with reference to obligations stated
to be payable in a currency other than U.S. dollars, that (i) a New York statute provides that a judgment rendered by a court of
the State of New York in respect of an obligation denominated in any such other currency is to be rendered in such other currency but
is then to be converted into U.S. dollars at the rate of exchange prevailing on the date of entry of the judgment and (ii) a judgment
rendered by a federal court sitting in the State of New York in respect of an obligation denominated in any such other currency will
be expressed in U.S. dollars, but we express no opinion as to the date of the rate of exchange such federal court will apply. Further
with respect to both a New York State court or a federal court, we express no opinion as to any rate of exchange that might be applied.
This opinion letter has been prepared for use
in connection with the Registration Statement. We assume no obligation to advise of any changes in the foregoing subsequent to the effective
date of the Registration Statement.
We hereby consent to the filing of this opinion
letter as Exhibit 5.1 to the Registration Statement and to the reference to this firm under the caption “Legal Matters”
in the prospectus constituting a part of the Registration Statement.
In giving this consent, we do not thereby admit
that we are an “expert” within the meaning of the Act.
Very truly yours,
/s/ HOGAN LOVELLS US LLP
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
We hereby consent to the incorporation by reference in this Registration
Statement on Form S-3 of Colgate-Palmolive Company of our report dated February 16, 2023 relating to the financial statements,
financial statement schedule and the effectiveness of internal control over financial reporting, which appears in Colgate-Palmolive Company’s
Annual Report on Form 10-K for the year ended December 31, 2022. We also consent to the reference to us under the heading “Experts”
in such Registration Statement.
/s/ PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP
New York, NY
October 27, 2023
Exhibit 24.1
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS:
I, John P. Bilbrey, do hereby make, constitute
and appoint Noel R. Wallace, Stanley J. Sutula III and Jennifer M. Daniels, and each of them, as my attorneys-in-fact and agents with
full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf Registration
Statements of Colgate-Palmolive Company (the “Company”) on Form S-3, or other appropriate forms, relating to the issuance
of debt securities authorized by the Board of Directors, and any and all amendments (including post-effective amendments) to such Registration
Statements and any other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done
in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents and/or any of them, may lawfully do or cause to be done by virtue hereof.
IN WITNESS WHEREOF, I have executed this Power of Attorney
this 13th day of September, 2023.
|
/s/ John P. Bilbrey |
|
Name: John P. Bilbrey |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS:
I, John T. Cahill, do hereby make, constitute
and appoint Noel R. Wallace, Stanley J. Sutula III and Jennifer M. Daniels, and each of them, as my attorneys-in-fact and agents with
full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf Registration
Statements of Colgate-Palmolive Company (the “Company”) on Form S-3, or other appropriate forms, relating to the issuance
of debt securities authorized by the Board of Directors, and any and all amendments (including post-effective amendments) to such Registration
Statements and any other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done
in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents and/or any of them, may lawfully do or cause to be done by virtue hereof.
IN WITNESS WHEREOF, I have executed this Power of Attorney
this 13th day of September, 2023.
|
/s/ John T. Cahill |
|
Name: John T. Cahill |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS:
I, Steven A. Cahillane, do hereby make, constitute
and appoint Noel R. Wallace, Stanley J. Sutula III and Jennifer M. Daniels, and each of them, as my attorneys-in-fact and agents with
full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf Registration
Statements of Colgate-Palmolive Company (the “Company”) on Form S-3, or other appropriate forms, relating to the issuance
of debt securities authorized by the Board of Directors, and any and all amendments (including post-effective amendments) to such Registration
Statements and any other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done
in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents and/or any of them, may lawfully do or cause to be done by virtue hereof.
IN WITNESS WHEREOF, I have executed this Power of Attorney
this 13th day of September, 2023.
|
/s/ Steven A. Cahillane |
|
Name: Steven A. Cahillane |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS:
I, Lisa M. Edwards, do hereby make, constitute
and appoint Noel R. Wallace, Stanley J. Sutula III and Jennifer M. Daniels, and each of them, as my attorneys-in-fact and agents with
full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf Registration
Statements of Colgate-Palmolive Company (the “Company”) on Form S-3, or other appropriate forms, relating to the issuance
of debt securities authorized by the Board of Directors, and any and all amendments (including post-effective amendments) to such Registration
Statements and any other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done
in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents and/or any of them, may lawfully do or cause to be done by virtue hereof.
IN WITNESS WHEREOF, I have executed this Power of Attorney
this 13th day of September, 2023.
|
/s/ Lisa M. Edwards |
|
Name: Lisa M. Edwards |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS:
I, C. Martin Harris, do hereby make, constitute
and appoint Noel R. Wallace, Stanley J. Sutula III and Jennifer M. Daniels, and each of them, as my attorneys-in-fact and agents with
full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf Registration
Statements of Colgate-Palmolive Company (the “Company”) on Form S-3, or other appropriate forms, relating to the issuance
of debt securities authorized by the Board of Directors, and any and all amendments (including post-effective amendments) to such Registration
Statements and any other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done
in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents and/or any of them, may lawfully do or cause to be done by virtue hereof.
IN WITNESS WHEREOF, I have executed this Power of Attorney
this 13th day of September, 2023.
|
/s/ C. Martin Harris |
|
Name: C. Martin Harris |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS:
I, Martina Hund-Mejean, do hereby make, constitute
and appoint Noel R. Wallace, Stanley J. Sutula III and Jennifer M. Daniels, and each of them, as my attorneys-in-fact and agents with
full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf Registration
Statements of Colgate-Palmolive Company (the “Company”) on Form S-3, or other appropriate forms, relating to the issuance
of debt securities authorized by the Board of Directors, and any and all amendments (including post-effective amendments) to such Registration
Statements and any other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done
in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents and/or any of them, may lawfully do or cause to be done by virtue hereof.
IN WITNESS WHEREOF, I have executed this Power of Attorney
this 13th day of September, 2023.
|
/s/ Martina Hund-Mejean |
|
Name: Martina Hund-Mejean |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS:
I, Kimberly A. Nelson, do hereby make, constitute
and appoint Noel R. Wallace, Stanley J. Sutula III and Jennifer M. Daniels, and each of them, as my attorneys-in-fact and agents with
full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf Registration
Statements of Colgate-Palmolive Company (the “Company”) on Form S-3, or other appropriate forms, relating to the issuance
of debt securities authorized by the Board of Directors, and any and all amendments (including post-effective amendments) to such Registration
Statements and any other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done
in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents and/or any of them, may lawfully do or cause to be done by virtue hereof.
IN WITNESS WHEREOF, I have executed this Power of Attorney
this 13th day of September, 2023.
|
/s/ Kimberly A. Nelson |
|
Name: Kimberly A. Nelson |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS:
I, Lorrie M. Norrington, do hereby make, constitute
and appoint Noel R. Wallace, Stanley J. Sutula III and Jennifer M. Daniels, and each of them, as my attorneys-in-fact and agents with
full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf Registration
Statements of Colgate-Palmolive Company (the “Company”) on Form S-3, or other appropriate forms, relating to the issuance
of debt securities authorized by the Board of Directors, and any and all amendments (including post-effective amendments) to such Registration
Statements and any other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done
in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents and/or any of them, may lawfully do or cause to be done by virtue hereof.
IN WITNESS WHEREOF, I have executed this Power of Attorney
this 13th day of September, 2023.
|
/s/ Lorrie M. Norrington |
|
Name: Lorrie M. Norrington |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS:
I, Stephen I. Sadove, do hereby make, constitute
and appoint Noel R. Wallace, Stanley J. Sutula III and Jennifer M. Daniels, and each of them, as my attorneys-in-fact and agents with
full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf Registration
Statements of Colgate-Palmolive Company (the “Company”) on Form S-3, or other appropriate forms, relating to the issuance
of debt securities authorized by the Board of Directors, and any and all amendments (including post-effective amendments) to such Registration
Statements and any other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done
in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents and/or any of them, may lawfully do or cause to be done by virtue hereof.
IN WITNESS WHEREOF, I have executed this Power of Attorney
this 13th day of September, 2023.
|
/s/ Stephen I. Sadove |
|
Name: Stephen I. Sadove |
Exhibit 25.1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM T-1
STATEMENT OF ELIGIBILITY
UNDER THE TRUST INDENTURE ACT OF 1939 OF A
CORPORATION DESIGNATED TO ACT AS TRUSTEE
CHECK IF AN APPLICATION TO DETERMINE
ELIGIBILITY OF A TRUSTEE PURSUANT TO
SECTION 305(b)(2) ¨
THE BANK OF NEW YORK MELLON
(Exact name of trustee as specified in its charter)
New York
(Jurisdiction of incorporation
if not a U.S. national bank) |
13-5160382
(I.R.S. employer
identification no.) |
240 Greenwich Street, New York, N.Y.
(Address of principal executive offices) |
10286
(Zip code) |
COLGATE-PALMOLIVE COMPANY
(Exact name of obligor as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization) |
13-1815595
(I.R.S. employer
identification no.) |
300 Park Avenue
New York, New York
(Address of principal executive offices) |
10022
(Zip code) |
Debt
Securities
(Title of the indenture securities)
| 1. | General information. Furnish the following information as to the Trustee: |
| (a) | Name and address of each examining or supervising authority to which it is subject. |
Name |
|
Address |
|
Superintendent of the Department of Financial Services of the
State of New York |
|
One State Street, New York, N.Y. 10004-1417, and Albany, N.Y. 12223 |
|
Federal Reserve Bank of New York |
|
33 Liberty Street, New York, N.Y. 10045 |
|
Federal Deposit Insurance Corporation |
|
550 17th Street, NW
Washington, D.C. 20429 |
|
The Clearing House Association L.L.C. |
|
100 Broad Street
New York, N.Y. 10004 |
| (b) | Whether it is authorized to exercise corporate trust powers. |
Yes.
| 2. | Affiliations with Obligor. |
If the obligor is an affiliate of
the trustee, describe each such affiliation.
None.
Exhibits identified in parentheses
below, on file with the Commission, are incorporated herein by reference as an exhibit hereto, pursuant to Rule 7a-29 under the Trust
Indenture Act of 1939 (the "Act").
| 1. | A copy of the Organization Certificate of The Bank of New York Mellon (formerly known as The Bank of New York, itself formerly Irving
Trust Company) as now in effect, which contains the authority to commence business and a grant of powers to exercise corporate trust powers.
(Exhibit 1 to Amendment No. 1 to Form T-1 filed with Registration Statement No. 33-6215, Exhibits 1a and 1b to Form T-1
filed with Registration Statement No. 33-21672, Exhibit 1 to Form T-1 filed with Registration Statement No. 33-29637,
Exhibit 1 to Form T-1 filed with Registration Statement No. 333-121195 and Exhibit 1 to Form T-1 filed with Registration
Statement No. 333-152735). |
| 4. | A copy of the existing By-laws of the Trustee (Exhibit 4 to Form T-1 filed with Registration
Statement No. 333-261533). |
| 6. | The consent of the Trustee required by Section 321(b) of the Act (Exhibit 6 to Form T-1
filed with Registration Statement No. 333-229519). |
| 7. | A copy of the latest report of condition of the Trustee published pursuant to law or to the requirements
of its supervising or examining authority. |
SIGNATURE
Pursuant to the requirements
of the Act, the trustee, The Bank of New York Mellon, a corporation organized and existing under the laws of the State of New York, has
duly caused this statement of eligibility to be signed on its behalf by the undersigned, thereunto duly authorized, all in the City of
New York, and State of New York, on the 20th day of October, 2023.
|
THE BANK OF NEW YORK MELLON |
|
|
|
|
By: |
/s/ Stacey B. Poindexter |
|
|
Name: |
Stacey B. Poindexter |
|
|
Title: |
Vice President |
EXHIBIT 7
Consolidated Report of Condition of
THE BANK OF NEW YORK MELLON
of 240 Greenwich Street, New York, N.Y. 10286
And Foreign and Domestic Subsidiaries,
a member of the Federal Reserve System, at the
close of business June 30, 2023, published in accordance with a call made by the Federal Reserve Bank of this District pursuant to
the provisions of the Federal Reserve Act.
| |
Dollar amounts in
thousands | |
ASSETS | |
| |
Cash and balances due from depository institutions: | |
| | |
Noninterest-bearing balances and currency and coin | |
| 4,283,000 | |
Interest-bearing balances | |
| 126,597,000 | |
Securities: | |
| | |
Held-to-maturity securities | |
| 53,162,000 | |
Available-for-sale debt securities | |
| 80,744,000 | |
Equity securities with readily determinable fair values not held for trading | |
| 0 | |
Federal funds sold and securities purchased under agreements to resell: | |
| | |
Federal funds sold in domestic offices | |
| 0 | |
Securities purchased under agreements to resell | |
| 19,336,000 | |
Loans and lease financing receivables: | |
| | |
Loans and leases held for sale | |
| 3,000 | |
Loans and leases held for investment | |
| 30,382,000 | |
LESS: Allowance for loan and lease losses | |
| 162,000 | |
Loans and leases held for investment, net of allowance | |
| 30,220,000 | |
Trading assets | |
| 4,969,000 | |
Premises and fixed assets (including capitalized leases) | |
| 2,820,000 | |
Other real estate owned | |
| 3,000 | |
Investments in unconsolidated subsidiaries and associated companies | |
| 1,229,000 | |
Direct and indirect investments in real estate ventures | |
| 0 | |
Intangible assets | |
| 6,942,000 | |
Other assets | |
| 18,318,000 | |
Total assets | |
| 348,626,000 | |
LIABILITIES | |
| | |
Deposits: | |
| | |
In domestic offices | |
| 193,689,000 | |
Noninterest-bearing | |
| 65,533,000 | |
Interest-bearing | |
| 128,156,000 | |
In foreign offices, Edge and Agreement subsidiaries, and IBFs | |
| 101,602,000 | |
Noninterest-bearing | |
| 5,813,000 | |
Interest-bearing | |
| 95,789,000 | |
Federal funds purchased and securities sold under agreements to repurchase: | |
| | |
Federal funds purchased in domestic offices | |
| 0 | |
Securities sold under agreements to repurchase | |
| 12,159,000 | |
Trading liabilities | |
| 2,642,000 | |
Other borrowed money: (includes mortgage indebtedness and obligations under capitalized leases) | |
| 2,492,000 | |
Not applicable | |
| | |
Not applicable | |
| | |
Subordinated notes and debentures | |
| 0 | |
Other liabilities | |
| 8,833,000 | |
Total liabilities | |
| 321,417,000 | |
EQUITY CAPITAL | |
| | |
Perpetual preferred stock and related surplus | |
| 0 | |
Common stock | |
| 1,135,000 | |
Surplus (exclude all surplus related to preferred stock) | |
| 12,112,000 | |
Retained earnings | |
| 18,070,000 | |
Accumulated other comprehensive income | |
| -4,108,000 | |
Other equity capital components | |
| 0 | |
Total bank equity capital | |
| 27,209,000 | |
Noncontrolling (minority) interests in consolidated subsidiaries | |
| 0 | |
Total equity capital | |
| 27,209,000 | |
Total liabilities and equity capital | |
| 348,626,000 | |
I,
Dermot McDonogh, Chief Financial Officer of the above-named bank do hereby declare that this Report of Condition is true and correct
to the best of my knowledge and belief.
|
Dermot McDonogh |
|
|
Chief Financial Officer |
|
We, the undersigned directors,
attest to the correctness of this statement of resources and liabilities. We declare that it has been examined by us, and to the best
of our knowledge and belief has been prepared in conformance with the instructions and is true and correct.
Robin
A. Vince
Jeffrey A. Goldstein
Joseph J. Echevarria
|
|
Directors |
Exhibit 107
Calculation of Filing
Fee Tables
Form S-3
(Form Type)
Colgate-Palmolive
Company
(Exact Name of Registrant
as Specified in its Charter)
Table 1: Newly Registered
and Carry Forward Securities
|
|
Security Type |
|
Security Class Title |
|
Fee Calculation or Carry Forward Rule |
|
Amount Registered(1) |
|
Proposed Maximum Offering Price Per Unit(1) |
|
Maximum Aggregate Offering Price(1) |
|
Fee Rate(2) |
|
Amount of Registration Fee(2) |
|
Carry Forward Form Type |
|
Carry Forward File Number |
|
Carry Forward Initial effective date |
|
Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward |
Newly Registered Securities |
Fees to Be Paid |
|
Debt |
|
Debt Securities |
|
Rule 456(b) and Rule 457(r) |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
|
|
|
|
|
|
Fees Previously Paid |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Carry Forward Securities |
Carry Forward Securities |
|
— |
|
— |
|
— |
|
— |
|
|
|
— |
|
|
|
|
|
— |
|
— |
|
— |
|
— |
|
|
Total Offering Amounts |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
Total Fees Previously Paid |
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
Total Fee Offsets |
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
Net Fee Due |
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
(1) |
An unspecified amount of the debt securities is being
registered as may from time to time be issued at indeterminate prices. |
(2) |
In accordance with Rules 456(b) and 457(r) under
the Securities Act of 1933, the registrant is deferring payment of all of the registration fee. |
Grafico Azioni Colgate Palmolive (NYSE:CL)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Colgate Palmolive (NYSE:CL)
Storico
Da Set 2023 a Set 2024